National Comprehensive Cancer Network (NCCN) Guidelines® Insights: Biliary Tract Cancers, Version 2.2023

Recommended molecular tests in advanced biliary tract cancers👇

Journal of the @NCCN OncoAlert

jnccn.org/view/journals/…

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline

📌Added update on amivantamab, mobocertinib and sotorasib

Journal of Clinical Oncology OncoAlert

ascopubs.org/doi/10.1200/JC…

Periop vs total neoadj chemo in gastric ca TNT feasible & w/o increase in surg complications ⁦Memorial Sloan Kettering Cancer Center⁩ ⁦MSK Department of Medicine⁩ 👏to Dr Yang, Ku & GE DMT! ⁦⁦Sam Cytryn⁩ ⁦ILSON David⁩ ⁦Daniela⁩ ⁦Vivian E. Strong, MD⁩ jgo.amegroups.com/article/view/7…

Very honored to receive this grant to improve cancer care for patients with Metastatic Breast Cancer in Mexico. Thanks to Conquer Cancer, the ASCO Foundation ASCO and Pfizer Inc. grants.INCMNSZ HEM ONC INCMNSZ

In Mexico, CRC represents the second leading cause of cancer death, no national CRC program exists. To overcome the cost-effectiveness barrier, risk-based CRC screening could be a answer #WCGIC2023 HEM ONC INCMNSZ

4-yr OS update from the phs 3 HIMALAYA trial of tremelimumab + durvalumab in HCC at #WCGIC2023
👉Excellent long-term survival data for STRIDE
👉4-yr OS rate of 19% (unprecedented in HCC)
👉Long-term OS observed in relevant subgroups, incl. pts with non-viral liver disease…

Amazing start of the seminar on GI cancers Memorial Sloan Kettering Cancer Center MSK ScienceEducation MSK CME with Dr. Moshe Shike today in #Salzburg 🙌🏻 AMSA #prevention 🇲🇽🇦🇹🇺🇸

🚨 Not to be missed! #ELCC23

📚 YO Clinical Case Discussion
📍5pm - Auditorium 15

Selected cases x 3 👇
🇲🇽 NSCLC - Ana K. Valenzuela
🇵🇱 MPM - #SylwiaTabor
🇫🇷 SCLC - Lodovica Zullo

Looking forward to discussions with our expert panel:
🇨🇭 Curioni_Oncology_MD
🇩🇪 Martin Reck

Also live 🎥!

Bravo 👏 to the 3️⃣ #YoungOncologists for the amazing clinical case presentation & discussion. #ELCC23

🇲🇽 Ana K. Valenzuela
🇵🇱 #SylwiaTabor
🇫🇷 Lodovica Zullo

Thank you to Prof Curioni_Oncology_MD & Prof Martin Reck for insightful discussions. More questions 💡 than answers perhaps 🤔 !

ROS1 recap! #NSCLC Approved, unapproved and 2nd gen in develop #ELCC23 #ELCC2023 ESMO - Eur. Oncology OncoAlert

Great debate today at #ELCC2023 about NEO chemo-IO vs adyuvant IO #NSCLC ESMO - Eur. Oncology

Now live: Robert Glynne-Jones & James Hollingshead discuss the RAPIDO trial of total neoadjuvant therapy in patients with locally advanced rectal cancer: nature.com/articles/s4157…

1️⃣

✳️I would like to dedicate my first tweetorial for Early onset CRC, as I truly believe it is an Epidemic that we know little about it❗️
✳️CRC is now the leading cause of cancer related death among males among aged 20-49 ❗️ CRC Change @oncoalert
#ColorectalCancerAwarenessMonth

Thursday March 2nd,2023: 20:00 (CST). Live from Mexico City.

Latin American School of Oncology Webinars.
2023 Post ASCO Gastrointestinal Cancers Symposium.

February 23rd, 21:00 (CST)

The Global Cholangiocarcinoma Alliance aims to establish a global voice for #cholangiocarcinoma – support them by signing the GCA pledge today & share it #BileDuctCancer globalccaalliance.com/en/get-involve…

#DiaMundialContraElCancer #WorldCancerDay2023 👊🏻👊🏻👊🏻

Los Esperamos!!!
XVI Curso Internacional de Cirugía 7-11 Feb. Presencial. Virtual. On Demand.

Slides! Retrospective study of short vs. long course RT for watch and wait at MSKCC.

Similar rates of initial complete response (46%), but response appears more durable with long course --> higher rates of organ preservation. Dose matters. #GI23 OncoAlert